-
公开(公告)号：US20240352067A1
公开(公告)日：2024-10-24
申请号：US18648015
申请日：2024-04-26
Applicant: RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY , KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
Inventor： Kwangho LEE , Sang Dal RHEE , Gildon CHOI , Imran ALI , Chong Hak CHAE , Moon Kook JEON , Seok Hee PARK , Youn Sook LEE
IPC: C07K5/117 , A61K38/00 , A61K47/54 , A61P1/00 , C07D207/04 , C07D403/06 , C07K5/097 , C07K5/103 , C07K5/107
CPC classification number: C07K5/1024 , A61K47/542 , A61P1/00 , C07D207/04 , C07D403/06 , C07K5/0823 , C07K5/1008 , C07K5/1016 , A61K38/00
Abstract: Pyrrolidine carboxamido derivatives, optical isomers thereof, and salts thereof that are able to prevent, improve, and/or treat inflammatory conditions, including inflammatory bowel disease, and methods for preparing and using the same are provided.
-
2.发明公开公开(公告)号：US20240254103A9
公开(公告)日：2024-08-01
申请号：US17914153
申请日：2021-03-12
Inventor： Ge Hyeong LEE , Jee Yeon SEO , Jeong Heon YU , In Hae YE , Ho Chul SHIN , Jee Hee SUH , Seong Hwan KIM , Jin Sook SONG , Seong Hyeon SIM , Chong Hak CHAE , Hee Yeon KANG , Ji Hun LEE , Keon Ha HWANG
IPC: C07D401/14 , C07D403/04 , C07D405/14 , C07D413/14 , C07D471/04 , C07D487/04 , C07D491/107 , C07D491/18
CPC classification number: C07D401/14 , C07D403/04 , C07D405/14 , C07D413/14 , C07D471/04 , C07D487/04 , C07D491/107 , C07D491/18
Abstract: The present invention relates to a novel pyrimidine derivative, and a composition for preventing or treating neurodegenerative diseases and cancer, comprising same, the pyrimidine derivative having a LRRK2 protein inhibitory activity, and effectively passing through a blood-brain barrier (BBB) so as to be effectively used as a pharmaceutical composition for preventing or treating neurodegenerative diseases and cancer.
-
公开(公告)号：US20180104242A1
公开(公告)日：2018-04-19
申请号：US15567224
申请日：2015-12-30
Inventor： Jong Yeon HWANG , Hyoung Rae KIM , Jae Du HA , Sung Yun CHO , Hee Jung JUNG , Pilho KIM , Chang Soo YUN , Chong Ock LEE , Chi Hoon PARK , Chong Hak CHAE , Sunjoo AHN
IPC: A61K31/506 , A61P35/00 , C07D239/48 , C07D239/30 , C07C13/48 , C07B43/04
CPC classification number: A61K31/506 , A23L33/10 , A61P35/00 , C07B43/04 , C07B2200/07 , C07C13/48 , C07D239/30 , C07D239/48
Abstract: The present invention relates to a 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.
-
Patent Agency Ranking
公开(公告)号：US20250145625A1
公开(公告)日：2025-05-08
申请号：US18725482
申请日：2022-12-30
Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY , UIF (UNIVERSITY INDUSTRY FOUNDATION), YONSEI UNIVERSITY
Inventor： Joon JEONG , Hye Kyoung SHIN , Sun Joo AHN , Hee Jong LIM , Jin Sook SONG , Seong Hwan KIM , Chong Hak CHAE , Eun Hye KIM , Ji Hye CHOI , Jong Seung LIM , Eun Soo JANG , Jin Woo SONG , Do Hyun KIM
IPC: C07D487/04 , A61K31/337 , A61K31/519 , A61K31/5377 , A61K45/06 , A61P35/00
Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of tumors, containing a novel pyrazolopyrimidine compound or a pharmaceutically acceptable salt thereof as an active ingredient. The pharmaceutical composition is administered in combination with other anticancer agents, and thus can be effectively used as a composition for preventing or treating cancer.
-
公开(公告)号：US20240352000A1
公开(公告)日：2024-10-24
申请号：US18579279
申请日：2022-07-11
Inventor： Kwangho LEE , Krishna Babu DUGGIRALA , Gildon CHOI , Yujin LEE , Chong Hak CHAE , Myoung Eun JUNG , Byoung Chul CHO
IPC: C07D401/14 , A61K31/506 , A61K45/06 , A61P35/00 , C07D403/12
CPC classification number: C07D401/14 , A61K31/506 , A61K45/06 , A61P35/00 , C07D403/12
Abstract: The present invention relates to a pyrimidine-2,4-diamine derivative, a method for preparing the same, and a pharmaceutical composition for preventing or treating cancer, comprising the same as an active ingredient. The pyrimidine-2,4-diamine derivative exhibits a high inhibitory ability against EGFR and HER2 mutations, and thus can be advantageously used in the treatment of cancer in which EGFR and HER2 mutations have occurred. In addition, the pyrimidine-2,4-diamine derivative exhibits a significant synergistic effect when administered in combination, and thus may be advantageously used in combination therapy.
-
6.发明公开公开(公告)号：US20230219930A1
公开(公告)日：2023-07-13
申请号：US17914153
申请日：2021-03-12
Inventor： Ge Hyeong LEE , Jee Yeon SEO , Jeong Heon YU , In Hae YE , Ho Chul SHIN , Jee Hee SUH , Seong Hwan KIM , Jin Sook SONG , Seong Hyeon SIM , Chong Hak CHAE , Hee Yeon KANG , Ji Hun LEE , Keon Ha HWANG
IPC: C07D401/14 , C07D403/04 , C07D405/14 , C07D491/107 , C07D413/14 , C07D491/18 , C07D487/04 , C07D471/04
CPC classification number: C07D401/14 , C07D403/04 , C07D405/14 , C07D491/107 , C07D413/14 , C07D491/18 , C07D487/04 , C07D471/04
Abstract: The present invention relates to a novel pyrimidine derivative, and a composition for preventing or treating neurodegenerative diseases and cancer, comprising same, the pyrimidine derivative having a LRRK2 protein inhibitory activity, and effectively passing through a blood-brain barrier (BBB) so as to be effectively used as a pharmaceutical composition for preventing or treating neurodegenerative diseases and cancer.
-
7.发明申请公开(公告)号：US20170145007A1
公开(公告)日：2017-05-25
申请号：US15319151
申请日：2015-05-21
Inventor： Chang Soo YUN , Hyoung Rae KIM , Sung Yun CHO , Hee Jung JUNG , Kwangho LEE , Chong Hak CHAE , Chong Ock LEE , Chi Hoon PARK , Pilho KIM , Jong Yeon HWANG , Jae DU HA , Sun Joo AHN
IPC: C07D471/04 , C07D405/14 , C07D401/14 , C07D403/12 , C07D401/12
CPC classification number: C07D471/04 , A61K31/506 , C07D209/04 , C07D239/12 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14
Abstract: The present invention relates to a pyrimidine-2,4-diamine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for prevention or treatment of cancer comprising the same as an effective ingredient. A compound according to the present invention has the good effect of inhibiting anaplastic lymphoma kinase (ALK) activity, whereby a therapeutic effect on cancer cells having an anaplastic lymphoma kinase (ALK) fusion protein such as EML4-ALK, NPM-ALK, etc. can be enhanced and it is expected that a recurrence of cancer will be effectively inhibited. As such, the compound can be effectively used in a pharmaceutical composition for prevention or treatment of cancer.
-
8.发明申请N2,N4-BIS(4-(PIPERAZINE-1-YL)PHENYL)PIRIMIDINE-2,4-DIAMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER 有权N2，N4-BIS（4-（哌嗪-1-基）苯基）吡啶-2,4-二胺衍生物或其药学上可接受的盐，以及作为活性成分的组合物，用于预防或治疗癌症公开(公告)号：US20150152069A1
公开(公告)日：2015-06-04
申请号：US14617079
申请日：2015-02-09
Inventor： Kwangho LEE , Hyoung Rae KIM , Chi Hoon PARK , Chong Ock LEE , Jong Kook LEE , Hee Jung JUNG , Sung Yun CHO , Chong Hak CHAE , Sang Un CHOI , Jae Du HA
IPC: C07D239/48
CPC classification number: C07D239/48 , A61K31/506 , C07D403/12 , C07D403/14
Abstract: Disclosed herein are a new N2,N4-bis(4-(piperazin-1-yl)phenyl)pyrimidin-2,4-diamine derivative or a pharmaceutically acceptable salt thereof and a pharmaceutical composition for the prevention or treatment of cancers containing the same as an active ingredient. The compound of the present invention has excellent inhibitory effects against the activities of anaplastic lymphoma kinase (ALK) and activated cdc42-associated kinase (ACK1) and thus can improve the therapeutic effects on the treatment of cancer cells having anaplastic lymphoma kinase fusion proteins such as EML4-ALK and NPM-ALK, and also effectively prevent the recurrence of cancers thus being useful as a pharmaceutical composition for the prevention and treatment of cancers.
Abstract translation: 本文公开了新的N 2，N 4 - 双（4-（哌嗪-1-基）苯基）嘧啶-2,4-二胺衍生物或其药学上可接受的盐和用于预防或治疗含有其的癌症的药物组合物 作为活性成分。 本发明的化合物对于间变性淋巴瘤激酶（ALK）和活化的cdc42相关激酶（ACK1）的活性具有优异的抑制作用，因此可以改善对具有间变性淋巴瘤激酶融合蛋白的癌细胞的治疗效果，例如 EML4-ALK和NPM-ALK，并且还有效地预防癌症的复发因此可用作用于预防和治疗癌症的药物组合物。
-
-
-
-
-
-
-
Search Results
8
records
(took 0.023 seconds)
